Company profile for MaaT Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating a range of cancers and Graft-versus-Host-Disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further ex...
MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating a range of cancers and Graft-versus-Host-Disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline, we have built a powerful discovery and analysis platform, GutPrint®, to evaluate drug candidates, determine novel disease targets and identify biomarkers.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
France
Address
Address
317 Avenue Jean Jaurès 69007 Lyon
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251104595960/en/MaaT-Pharma-Presents-Updated-Preclinical-Data-at-SITC-Annual-Meeting-Demonstrating-Immune-Activation-and-Anti-Tumor-Activity-of-MaaT034

BUSINESSWIRE
05 Nov 2025

https://www.businesswire.com/news/home/20251103278390/en/MaaT-Pharma-Announces-Positive-Phase-3-Results-Evaluating-Xervyteg-MaaT013-in-Acute-Graft-versus-Host-Disease-Selected-for-Oral-Presentation-at-ASH-Congress-2025

BUSINESSWIRE
03 Nov 2025

https://www.pharmiweb.com/press-release/2025-10-07/maat-pharma-announces-positive-second-safety-interim-analysis-from-dsmb-for-phase-2b-phoebus-trial-e

PHARMIWEB
07 Oct 2025

https://www.businesswire.com/news/home/20250727461196/en/MaaT-Pharma-Secures-%E2%82%AC37.5-Million-Loan-From-European-Investment-Bank-EIB-Marking-a-New-Step-in-Advancing-its-Clinical-Program-in-Hemato-Oncology

BUSINESSWIRE
28 Jul 2025

https://www.businesswire.com/news/home/20250702395509/en/MaaT-Pharma-Announces-Exclusive-Commercialization-Partnership-With-Clinigen-for-Xervyteg-in-acute-Graft-versus-Host-Disease-in-Europe

BUSINESSWIRE
02 Jul 2025

https://www.businesswire.com/news/home/20250624262451/en/MaaT-Pharma-Presents-the-Results-of-its-Annual-Ordinary-and-Extraordinary-General-Meeting

BUSINESSWIRE
24 Jun 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty